Format

Send to

Choose Destination
Eur J Radiol. 2012 Sep;81(9):2411-6. doi: 10.1016/j.ejrad.2011.07.018. Epub 2011 Sep 6.

Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis.

Author information

1
Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.

Abstract

AIM:

The purpose of the current study was to conduct a systemic review and meta-analysis of the published literature to evaluate the diagnostic accuracy of FDG PET or PET/CT in urinary bladder cancer.

MATERIALS AND METHODS:

The authors conducted a systematic MEDLINE search of articles published between January 2000 and December 2010. Two reviewers independently assessed the methodological quality of each study. We conducted a meta-analysis of pooled sensitivity and specificity in detecting primary and metastatic lesions of bladder cancer.

RESULTS:

Six studies met the inclusion criteria. The pooled sensitivity and specificity of PET/CT for primary lesion detection of bladder cancer were 0.90 (95% CI: 0.70-0.99) and 1.00 (95% CI: 0.74-1.00), respectively. The pooled sensitivity and specificity of FDG PET or PET/CT for staging or restaging (metastatic lesions) of bladder cancer were 0.82 (95% CI: 0.72-0.89) and 0.89 (95% CI: 0.81-0.95), respectively.

CONCLUSION:

The diagnostic accuracy of FDG PET or PET/CT is good in metastatic lesions of urinary bladder cancer. Due to the small number of patients and limited number of studies analyzed, the diagnostic capability of FDG PET or PET/CT in detection of primary bladder wall lesions could not be assessed.

PMID:
21899971
DOI:
10.1016/j.ejrad.2011.07.018
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center